This information determines whether GLP-1s are appropriate for you
This should initially occur at one month and subsequently every four months
We'll schedule your follow-up to monitor progress
Now you might wonder, "What makes each GLP-1 different, and which is right for me?" That must be a discussion between you and your doctor, as a 2021 review 7 tells us the most notable differences between GLP-1 receptor agonistslike pharmacokinetics 8 (how the body interacts with the medication), dosing frequency, and administrationcan impact the GLP-1 RA's efficacy, tolerability, and patient satisfaction
In one trial, around 800 people received weekly semaglutide injections accompanied by dietary adjustments, a prescribed exercise regime and psychological counselling, all of which helped them to lose nearly 11% of their starting weight over four months
"Some can maintain on a lower dose, while others require ongoing therapy at their current dose." If you're like me and squeamish about the prospect of weekly injections indefinitely, take note that oral GLP-1s are now on the market: the Food and Drug Administration (FDA) approved oral Wegovy in December 2025 and Foundayo (orforglipron) in April 2026